JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 214 filers reported holding JUNO THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is 0.99 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $85,952,000 | -2.2% | 1,880,373 | -4.0% | 0.02% | -7.7% |
| Q3 2017 | $87,905,000 | +103.0% | 1,959,564 | +35.3% | 0.03% | +100.0% |
| Q2 2017 | $43,301,000 | +13.4% | 1,448,652 | -15.8% | 0.01% | +116.7% |
| Q1 2017 | $38,168,000 | +5.3% | 1,720,096 | -10.5% | 0.01% | 0.0% |
| Q4 2016 | $36,238,000 | +13.2% | 1,922,374 | +80.2% | 0.01% | -45.5% |
| Q3 2016 | $32,014,000 | -27.5% | 1,066,747 | -7.2% | 0.01% | -31.2% |
| Q2 2016 | $44,186,000 | -7.6% | 1,149,502 | -8.4% | 0.02% | -11.1% |
| Q1 2016 | $47,802,000 | +306.8% | 1,254,965 | +369.7% | 0.02% | +350.0% |
| Q4 2015 | $11,750,000 | +7.8% | 267,210 | -0.2% | 0.00% | 0.0% |
| Q3 2015 | $10,897,000 | +51.7% | 267,833 | +98.8% | 0.00% | +100.0% |
| Q2 2015 | $7,183,000 | +16.5% | 134,703 | +32.5% | 0.00% | 0.0% |
| Q1 2015 | $6,165,000 | -52.9% | 101,644 | -59.4% | 0.00% | -60.0% |
| Q4 2014 | $13,081,000 | – | 250,516 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |